Finally, we investigated the potency of our set of TCE-encoding oAds for T cell-mediated killing of NSCLC cells, as dual-targeting of c-MET and EGFR is clinically established for the treatment of NSCLC patients, but modalities with reduced systemic side effects are warranted.58 The gene discussed is MET; the disease is non-small cell lung carcinoma.